A Phase â…¡ Study of F520 in Patients With Cervical Carcinoma
This study was an open, single-arm, enriched, multicenter Phase II study.
Cervical Cancer
DRUG: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Objective tumor response rate (ORR) assessed by RECIST1.1, CR+PR, approximately 2 years
The trial was divided into screening period, treatment period and follow-up period. Participants entered the screening period after signing informed consent and met the inclusion criteria. Subjects who did not meet the exclusion criteria were treated with F520 monotherapy, intravenously, at 3mg/kg every 3 weeks until disease progression or intolerable toxicity or withdrawal for other reasons, for a maximum of 2 years.